Some cases of LCNEC carrying EGFR gene activation mutations have been reported to have good efficacy against EGFR-tyrosine kinase inhibitors (TKIs) (71–75), and ALK inhibitors have also been effective in treating LCNEC cases carrying ALK rearrangements (76). This evidence concerns the gene ALK and large cell neuroendocrine carcinoma.